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Abstract 
 
Ulcerative colitis is a chronic idiopathic inflammatory disorder of the colon with a relapsing 
remitting course.  It affects 40,000 Australian patients currently.
1
 During their disease course 1 in 5 
of these patients develop a severe episode of colitis requiring hospital admission and a significant 
proportion of them 19-40 % require resection of the colon to remain healthy.
2
 The colectomy rate of 
acute severe ulcerative colitis (ASUC) continues to remain high despite significant advances in 
medical therapy over the last three decades.  Risk stratification and optimal treatment strategy 
remain clinical challenges.  It has been suggested by some authors that patients established on 
immunosuppressive therapy at the time of severe ulcerative colitis are a higher risk for colectomy 
than those not on treatment.
3
 Over half the patients admitted for this condition are on treatment at 
the time of admission but the outcomes of these patients have not been well studied.  In addition 
many patients are transferred to large tertiary metropolitan hospitals from smaller regional hospitals 
which lack inflammatory bowel disease or gastroenterology specialty input.  The initial 
management of these patients is therefore undertaken in these regional hospitals and the effect of 
this on colectomy rates not currently known. 
This thesis firstly aimed to identify whether being on immunosuppressive treatment at the time of 
admission with ASUC increases the risk of colectomy.  Secondly this thesis aimed to compare the 
colectomy rates of ASUC patients presenting initially to regional with those presenting directly to a 
metropolitan tertiary hospital.  We aimed to identify the driving factors for any inequality to allow 
development of strategies to improve the outcome of regional patients with this condition. 
Our findings show that immunosuppressive therapy prior to admission with ASUC does not 
significantly increase the colectomy rate.  Predictors of colectomy confirmed were colonic dilation 
≥ 5.5cm, transfer from a regional hospital, CRP level ≥ 45 mg/ml on day 3 of admission, first 
presentation of ulcerative colitis and bowel action frequency ≥ 8 on day 3 of treatment. Knowledge 
of these key parameters allows the clinician to select high risk patients for early and aggressive 
rescue therapy, stomal therapist and colorectal surgeon review.  
In regards to our second aim we found that regional transfer patients were three times as likely to 
undergo colectomy as patients presenting directly to our metropolitan hospital at 30 days post 
admission.  The primary factor identified was poor response to intravenous steroids.  Predictors of 
colectomy in regional transfer patients identified were bowel frequency ≥ 8 on day 3 and CRP ≥  45 
mg/L on day 3 of therapy.  
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Introduction 
 
Acute severe ulcerative colitis (ASUC) is a life and colon threatening inflammatory condition with 
a high colectomy rate of 19-40 % stable over the last 30 years despite significant advances in 
medical management.
4
  Intensive medical management in the modern era has reduced the mortality 
to 1-2 % in specialist centres but mortality can be significantly higher in non-specialist centres as 
evidenced by a review of a British district hospitals severe colitis patients in 2001 demonstrating six 
deaths in a six year period with a mortality of 24 %. 
5
 
6
 
ASUC occurs in 1 in 5 patients with ulcerative colitis (UC) during their disease course and accounts 
for 70 % of hospitalizations. 
6, 7
  In these patients 55 % are on treatment with oral corticosteroids or 
an immunomodulator at the time of admission.
6
 Little data is available on the effect of treatment 
immediately prior to hospitalization on colectomy rate and none examining it using prospectively 
collected data. The first aim of this project examines the association between immunosuppression 
prior to admission and colectomy rate.   
This issue is of key importance in the risk stratification process of patients being admitted with 
severe ulcerative colitis. A number of predictors of colectomy have been identified but the ability to 
predict the outcomes of individual patients still remains challenging. In 25 % of patients it is not 
possible to predict the outcome of the severe attack of colitis.  Respected authors in this field have 
suggested that patients already receiving treatment at the time of a severe episode of ulcerative 
colitis may be at higher risk than patients not receiving treatment and thus could be treated more 
aggressively.
3
  There are little data published on this and this was selected as the primary research 
question for the first aim of this project. 
The second aim of this project looks at outcomes for patients with ASUC presenting first to a 
regional hospital and then being transferred to a metropolitan tertiary hospital part way through 
their care.  As our geographical area of Queensland has a high land mass compared to population 
density there are significant barriers to optimal care including geographic isolation from medical 
specialists, patient and physician perception of illness severity and delayed patient presentation.
8
  It 
would therefore be important to evaluate outcomes of these patients and if there is a significant 
difference in outcome to try and identify modifiable factors which could ensure better outcomes for 
regional patients with ASUC.   
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Literature review 
 
Colectomy rate in ASUC 
The colectomy rate in comparable cohorts of acute severe ulcerative colitis patients defined by 
Truelove and Witt criteria is reported at 19 – 40 %. 9  10, 11   
 
Effect of oral corticosteroids on colectomy rate 
 
Oral corticosteroids are commonly prescribed to induce remission in active ulcerative colitis prior 
to admission as evidenced by the United Kingdom national clinical audit of inpatient care showing 
33 % are on this treatment at time of admission. 
6
  Oral corticosteroid therapy although effective for 
induction of remission in mild-moderate cases of active ulcerative colitis is not particularly 
effective in inducing remission in severe ulcerative colitis.  This was demonstrated by Kjeldsen at el 
in their 1993 review of 89 severe ulcerative colitis patients treated with oral prednisolone showing a 
remission rate of 47 % and colectomy rate 24 % at 2 years. This compares with mild-moderate 
patients in the same cohort which had high remission rates of > 80 % with oral steroids and lower 
colectomy rates of 3-13 % 
12
  
In a Korean study of moderate ulcerative colitis patients (less severe than our study population) who 
had failed oral corticosteroid therapy and went on to have intravenous steroid therapy 46 % of 
patients were in remission at 1 year and 42 % of patients could not achieve steroid free remission 
and steroid dependant with 9 % refractory to treatment at 1 year with no steroid response.  Oral 
corticosteroid use > 14 days and Haemoglobin < 110 g/dl were identified as poor prognostic factors 
in this patient cohort. 
13
 
A large population based cohort study over 10 years following incident cases of ulcerative colitis 
found that patients requiring oral corticosteroid use soon after diagnosis were 2.9 times more likely 
to have a colectomy and 4.9 times more likely to be steroid dependant within 5 years than those 
who did not.  
14
 
No studies have looked directly at use of oral corticosteroids prior to admission with ASUC and 
colectomy rates after standard treatment with intravenous steroid and rescue therapy with infliximab 
or ciclosporin in case of intravenous steroid failure.   
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Effect of immunomodulators on colectomy rate 
No studies have looked specifically at the effect of immunomodulator therapy on the colectomy rate 
of the ASUC patient population overall.  Immunomodulators most notably the thiopurines  
(Azathioprine, Mercaptopurine and thioguanine) are effective agents in maintaining clinical and 
biochemical remission in patients who have had an episode of moderate-severe ulcerative colitis.
15
 
They are slow to act and therefore not useful in inducing remission in ASUC but appear to be 
effective in preventing relapse and maintain steroid free remission.  Multiple prior studies including 
two controlled trials have shown that treatment with a thiopurine can reduce or eliminate steroid use 
over time and maintain long term steroid free remission. 
16-20
 In the landmark study by Pannacione 
et al thiopurine use in combination with infliximab therapy was demonstrated to increase clinical 
remission, clinical response and mucosal healing when compared with Infliximab or thiopurine 
monotherapy.
21
      
 
No studies have looked at an overall cohort of ASUC patients to determine the effect of prior 
immunomodulator treatment.  Multiple studies have however looked at the effect of prior 
immunomodulator use on the outcome of ASUC in intravenous steroid refractory ulcerative colitis 
receiving rescue therapy.  In these studies sub-analysis with very small numbers showed no 
significant increase in colectomy rate when infliximab was used as rescue therapy.  
22-24
  A single 
large retrospective study looking at patients receiving cyclosporine rescue therapy by Moskowitz et 
al demonstrated a higher 1 year colectomy rate of 59 % in patients already on azathioprine 
compared to 35 % for those started azathioprine de novo at the time of rescue therapy with 
cyclosporine. 
25
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Effect of regional versus metropolitan mode of presentation on colectomy rate 
It is estimated that in Australia 1 in 10 inflammatory bowel disease patients lives in an outer 
regional or remote location which makes access to specialist healthcare challenging especially in a 
complex condition such as ulcerative colitis.
26
  Queensland has a particular issue due to large land 
mass with 39 % of the total number of inflammatory bowel disease patients living in regional or 
remote Queensland.  
26
    
Poorer outcomes have been demonstrated in a number of chronic diseases in Australian rural and 
regional patients including asthma, COPD, post myocardial infarction and cancer related deaths of 
all causes.
27-29
  It is likely that regional and rural inflammatory bowel disease patients may have 
similarly worse outcomes due to geographic isolation and lack of specialist care.  In addition 
regional and rural patients may have their condition diagnosed later than metropolitan patients and 
may have optimal treatment delayed affected outcome. 
An epidemiological study from the United Kingdom looking at patients admitted to a regional 
hospital with ASUC found a mortality of 9.2 % at 1 year and 20 % at 5 years. 
30
  There was no 
significant link between mortality and social deprivation, distance to hospital, urban/rural residence 
and geographic location. 
30
  The mortality in this study however is significantly higher than 
published mortality rates in specialist tertiary hospitals in the United Kingdom who have a 1-2 % 
mortality rate but consistent with other reports from United Kingdom regional hospitals. 
6
 
5
    There 
is other data showing that post-operative mortality is lowest in centres that perform a high volume 
of operations which also has relevance to the regional versus metropolitan issue in regard to 
ulcerative colitis and colectomy. 
31
  
There is epidemiological data from the United States examining over 20,000 ulcerative colitis 
patient admissions to hospital demonstrating that colectomy rates vary by race and geographic 
location.  Hispanic and African American patients were more likely to undergo colectomy and have 
a longer delay between admission and colectomy compared to Caucasian patients.  Colectomy rates 
varied by geographic location as well with patients in the west and Midwest undergoing colectomy 
3 times more than patients in the Northeast.
32
  In addition patients were more likely to undergo 
colectomy if admitted to an urban hospital rather than a rural, a larger hospital compared to a 
smaller hospital and a teaching hospital versus a non-teaching hospital. 
32
 
There are no direct studies looking at colectomy rates in regional versus metropolitan presenting 
patients with ASUC which this study hopes to address.    
14 
 
 
Hypotheses generation 
 
From the review of literature it became apparent that there is a paucity of published data to guide 
clinical management of patients on immunosuppressive therapy presenting with acute severe 
ulcerative colitis. A large single center retrospective study even concluded that it could be harmful 
to administer rescue therapy with ciclosporin to patients failing intravenous steroids established on 
an immunomodulator, demonstrating a significantly worse outcome in terms of colectomy rates.
25
  
This has led many treatment algorithms to suggest avoiding ciclosporin rescue therapy in these 
patients.  The rest of the evidence suggests no significant worsening in outcome which leaves 
clinicians in doubt when faced with such a patient.   
In addition anecdotally when managing these patients there is the impression that they may be more 
difficult to treat than patients not on an immunosuppressant at the time of admission.  This can lead 
to incorrect risk stratification and is based on clinical dogma rather than objective evidence of a 
poor outcome.   Our hypothesis was that patients established on an immunosuppressive medication 
(either an immunomodulator or oral steroid) would be more difficult to treat and thus be more likely 
to fail medical therapy and come to colectomy.   
In regards to outcomes of regional patients with severe ulcerative colitis the literature again is 
sparse.  There is a single small cohort study from a British regional hospital demonstrating 
significantly increased peri-operative mortality in patients managed regionally compared to in large 
tertiary centers but there is no data in regards to colectomy rates.  This issue has significance as 
many of our patients are transferred from regional hospitals over a vast area with the effect on their 
outcome unknown.   
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Statement of hypotheses  
 
1. Patients on treatment with an immunomodulator or oral corticosteroid at the time of 
admission would be more refractory to treatment and more likely to fail medical therapy and 
come to colectomy than those naïve to immunosuppression.  
 
2. Patients presenting to a regional hospital requiring transfer compared to those presenting to 
a metropolitan tertiary centre would have a higher colectomy rate at 30 days due to failure of 
initial intravenous steroid therapy   
 
 
 
Projects aims 
 
 
1. To determine using prospective data if immunosuppressive therapy prior to admission with 
severe colitis affects the colectomy rate at 30 days  
2. To evaluate the effect of regional hospital transfer versus tertiary metropolitan hospital 
initial presentation on 30 day colectomy rate in patients with severe ulcerative colitis and 
identify any causative factors for any difference 
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Methodology 
 
Data collection and entry 
Data has been collected prospectively on consecutive patients with ASUC admitted to the Royal 
Brisbane and Women’s hospital a tertiary referral centre from January 1996 – May 2014.    Patients 
are identified by the inflammatory bowel disease team at the weekly inpatient meeting and a pre-
defined list of variables entered by the inpatient medical team during their admission. This data is 
entered into a secure inflammatory bowel disease database “IBD Prime” under a research 
programme created by Associate Professor Graham Radford-Smith. A wide range of parameters has 
been collected over this time period including clinical, biochemical, genotypic, radiologic and 
endoscopic data a subset of which was used to examine the research questions in this thesis.  
Written informed consent was obtained from all patients included in this study and the study 
protocol approved by the Royal Brisbane and Women’s hospital medical ethics committee.   
 
20 parameters were collected which can be grouped into the following categories: 
 
1. Medication use:  Oral steroid, oral 5-ASA, Immunomodulator use for 4 months prior to 
admission.        
 
2. Clinical phenotype :  Age, gender, smoking status, disease duration, first presentation of 
ulcerative colitis status and extent of disease  
 
3. Admission related data:  Clinical parameters were collected and Laboratory parameters were 
accessed from the AUSLAB pathology system, radiology results were accessed from the 
PACS system.  Parameters were collected on day 1- 3 of admission: ESR, CRP, Albumin, 
Haemoglobin, Temperature, Heart rate, Abdominal radiograph result, Details of rescue 
therapy if given and duration of intravenous steroid use. The inflammatory bowel disease 
database “IBD PRIME” was also cross referenced for any missing parameters not located in 
the systems listed above.  
 
 
17 
 
4. Outcome related data:  Colectomy rate at 30 days post admission to RBWH 
 
 
In patients transferred for care from regional hospitals all relevant clinical and laboratory data was 
requested and entered prospectively into our database for later analysis. Patients were followed up 
clinically until 30 days post discharge and their outcomes recorded. All prospectively collected data 
will then analysed retrospectively.   Data was not collected in regards to mortality, length of stay or 
operative complications. 
 
 
Cohort selection  
The severe ulcerative colitis patients in the study are a subset selected from a large cohort of 
inflammatory bowel disease patients which have been managed and had their data prospectively 
entered since 1996 after creation of the inflammatory bowel disease program at the Royal Brisbane 
and Women’s hospital by Associate Professor Graham Radford-Smith.  In this study cases were the 
index ASUC episode for each patient and therefore patient’s subsequent admissions were not 
included.   
 
Cohort size  
 
Our cohort size of 200 patients is determined by the number of patients who met our inclusion 
criteria.  It is comparable to other cohorts of acute severe colitis published in the literature in terms 
of size and will be able to give an indication of the effect of treatment and mode of presentation on 
the outcomes of these patients.   A calculation of statistical power was not performed as it would 
not have changed our approach as there is no capacity to increase the cohort size of a prospectively 
collected real life cohort of patients.   
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Cohort derivation 
Aim 1 
 
Aim 2 
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Statistical approach  
 
Aim 1 
Demographic and clinical parameters of the cohort were compared between those who either had or 
did not have a colectomy at the 30-day endpoint. Age at the time of admission was compared using 
the independent samples t-test, disease duration was compared using the Mann Whitney U test, 
while all other parameters were compared using the Chi-Square test. Odds ratio’s (95% confidence 
intervals (95%CI)) are presented to define effect sizes and estimated error for each parameter to 
predict outcome. Multivariate analyses were conducted using the stepAIC function with the 
Generalised Linear Model (binomial GLM) to ascertain the optimum combination of biomarker 
associated with colectomy. Bonferroni correction was applied to the comparative alpha value, such 
that p-values were compared to an adjusted alpha (=0.05/ K (K=number of characteristics tested), 
0.05/18 = 0.00278). All statistical analyses were conducted using the R statistical environment 
Version 3.2.3
33
  
 
 
Aim 2 
Sample demographic and clinical parameters were assessed between metropolitan and regional 
groups. Laboratory parameters including bowel actions, C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), albumin and haemoglobin were assessed between colectomy/no 
colectomy at 30 days, stratified by whether patients initially presented to a metropolitan or regional 
hospital. Quantitative parameters were assessed either via the independent samples t-test or the 
Mann Whitney U test, while categorical factors were assessed with the Chi square test. Laboratory 
parameters were transformed into binary factors based upon previously defined thresholds. 
Adjustment for multiple comparisons was performed separately for metropolitan vs regional, and 
colectomy vs no colectomy comparisons, whereby the comparative alpha was divided by the 
number of parameters tested (origin: =0.05/20 (0.0025), colectomy: =0.05/7 (0.007)). All 
statistical analyses were performed using the R statistical environment (version 3.2.3).
33
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Rationale for pre-determined cut-off selection for laboratory and clinical values 
 
Clinical and laboratory parameters were assessed in a binary manner, using previously published 
thresholds in comparable cohorts of ASUC patients, with a 0 referring to low risk, and 1 referring to 
high risk.  This was approach was chosen was as the aim of this study was not to develop new predictive 
markers of colectomy but to examine the effect of immunosuppressive therapy and regional versus 
metropolitan hospital origin on colectomy rate.  We chose the most effective and reproducible clinical 
and biochemical markers that have been demonstrated in the literature from similar ASUC cohorts as 
closely correlating with colectomy to demonstrate the effect of the variables of interest in this case 
immunosuppression and regional versus metropolitan hospital origin.   
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Manuscript (Aim 1):   Pre-admission immunosuppression does not affect the 
outcome of acute severe ulcerative colitis 
 
Significance of this study 
What is already known on this subject? 
 19-40 % of patients still fail medical therapy and undergo early colectomy   
 Risk stratification and prediction of medical therapy failure remain vital in the optimal 
management of acute severe ulcerative colitis (ASUC) to allow early rescue therapy 
administration and timely and frank discussions with colorectal surgeons  
 Immunosuppressive treatment status on admission may help to guide risk stratification and 
selection of patients for early and more aggressive therapy but its effect on colectomy rate is 
currently unknown 
What are the new findings? 
 Immunosuppressive treatment with an immunomodulator or oral steroids prior to admission 
does not significantly increase the colectomy rate  
 First presentation of UC is associated with a higher risk of colectomy than severe flares of 
known UC 
 
How might it impact on clinical practice in the foreseeable future? 
 Risk stratification based on baseline immunosuppression at the time of presentation with 
ASUC is not useful in predicting colectomy 
 
 Patients should be selected for early and aggressive rescue therapy based on the high risk 
features confirmed in this study  
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Abstract 
Background and aims:  Patients on immunosuppression at the time of ASUC have been suggested 
to be at a higher risk of colectomy than those who are treatment naïve. The aim of this study was to 
examine the effect of immunosuppressive therapy on the risk of colectomy. 
Method:  We conducted an observational cohort study examining the 30 day colectomy rate using 
prospective data on 200 consecutive patients with an index episode of acute severe ulcerative colitis 
defined by Truelove and Witts’ criteria.  
Results: Immunosuppression on admission was shown not to be an important predictor of 
colectomy at 30 days post-admission (immunomodulator: P = 0.422, oral steroids: P= 0.555). 
Predictors of colectomy from multivariate analysis included:  Colonic dilation ≥ 5.5 cm on 
abdominal radiograph: OR 4.0 (95 % CI: 1.46 – 10.96; P = 0.007), transfer from a regional hospital: 
OR 2.39 (95% CI 1.18 – 4.83; P = 0.016), CRP ≥ 45 mg/L on day 3: OR 2.41 (95% CI: 1.15 – 5.08; 
P = 0.02),  first presentation of ulcerative colitis: OR 2.21 (95 % CI: 1.05 – 4.68; P = 0.037) and 
bowel frequency on day 3 ≥ 8: OR 2.1 (95 %CI: 1.03–4.29; P = 0.041).   
Conclusion:  Immunosuppression status on admission does not predict colectomy and cannot be 
used in risk stratification.  Patients with the high risk features identified in this study should be 
selected for early and aggressive rescue therapy given their higher risk of early colectomy. 
 
Keywords: Corticosteroids; Immunomodulator therapy ; Ulcerative colitis; Colectomy                       
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Introduction 
Acute severe ulcerative colitis (ASUC) is common, occurring in 1 in 5 patients with ulcerative 
colitis (UC) during their disease course and accounting for 75 % of hospitalizations.
34
  Of these 
patients 19-40 % will come to colectomy after failing medical therapy.
10, 35, 36
   
Over half the patients admitted with ASUC are taking immunosuppressive treatment at the time of 
admission.
34, 35
  Respected authors in this field have suggested that patients on immunosuppressive 
therapy at the time of ASUC may be at higher risk for colectomy than immunosupression naïve 
patients.
3, 37
 This study explores the question: Is the outcome of a patient treated oral steroids or 
immunomodulator therapy prior to admission comparable to a patient not on these agents?   
There is discordance in the literature regarding the effect of immunosuppression on ASUC on 
outcome.  There are data to show that oral steroid use prior to admission is associated with a higher 
colectomy rate but this is limited to a few studies and key confounders were not accounted for. 
14, 38
  
Immunomodulator treatment at the time of admission has not been demonstrated to significantly 
increase the colectomy rate in the majority of studies.
22-24, 39
  There is a single large retrospective 
study demonstrating a 24 % higher one-year colectomy rate in patients presenting with ASUC 
established on an immunomodulator compared with immunomodulator-naïve patients receiving 
ciclosporin rescue therapy.
25
  This issue requires clarification for clinicians assessing, risk- 
stratifying and treating patients with ASUC.     
We hypothesized that patients already on immunosuppression at the time of hospitalization with 
ASUC would be more likely to fail medical therapy and require colectomy. Knowledge of the effect 
of immunosuppressive treatment on the outcome of ASUC would help clinicians to better risk 
stratify patients and personalize medical therapy to avoid colectomy. To address this clinical 
question we conducted a restrospective observational cohort study using prospective data to 
determine the colectomy rate at 30 days post-admission in immunosupressed versus non-
immunosupresessed patients with ASUC.  
 
 
 
 
 
24 
 
Methods 
A retrospective observational cohort study was conducted. Conduct of this study was approved by 
the Royal Brisbane and Women’s Hospital (RBWH) Ethics Committee.  All patients provided 
written informed consent.  Data were collected prospectively on consecutive patients with their 
index ASUC episode managed at the RBWH (Brisbane, Australia), a metropolitan hospital 
providing secondary and tertiary care from January 2000 – May 2014.  All subjects were followed 
by clinical outpatient review until 30 days post admission. By this time, subjects had either 
undergone a colectomy or were censored.   
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Definitions 
Immunosuppressive treatment prior to hospitalization 
Immunomodulator therapy was defined as being on a stable dose of azathioprine, mercaptopurine, 
thioguanine, methotrexate or mycophenelate for at least 4 months prior to admission.  Oral steroid 
treatment was defined as oral prednisolone use of 40mg for at least 5 days prior to admission.   
 
Treatment response  
Complete intravenous steroid response was defined as < 4 bowel actions per day without blood 
assessed on day 4 of intravenous steroid treatment.  Incomplete intravenous steroid response was 
defined as ≥ 4 bowel actions per day with or without blood assessed on day 4 of treatment.  Patients 
with < 4 bowel actions per day but with blood were considered incomplete intravenous steroid 
responders.   
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Case selection 
Hospitalized patients aged ≥ 18 years old with an index episode of ASUC meeting Truelove and 
Witts’ criteria on admission with at 30 days of follow-up were included. Disease extent was defined 
as maximal endoscopic or radiographic extent of disease at the time of admission.
40
  In addition all 
patients had to demonstrate a Mayo endoscopic score of ≥ 2 on their admission flexible 
sigmoidoscopy.   Abdominal radiographic colonic dilation was defined as maximal transverse colon 
diameter ≥ 5.5cm demonstrated on plain abdominal radiograph during the first 3 days of admission. 
41, 42
.  Patients who had received prior therapy with either infliximab or ciclosporin were excluded 
from the study.  Patients with concomitant enteric infection as proven on stool microscopy and 
culture including clostridium difficile toxin were excluded from the study. (Figure 1) 
 
Inpatient Management  
 
Patients were treated with our department’s standard protocol for management of ASUC including 
intravenous hydrocortisone 100 mg four times daily for 3-5 days with prophylactic heparin and 
close monitoring and replacement of electrolytes during the admission (Figure 2).
43
  This 
management protocol was consistent over the 14 years included in this study. Incomplete 
intravenous steroid responders on day 4 of treatment were treated with rescue therapy with 
ciclosporin infusion at 4 mg/kg (2000 -2003) or 2 mg/kg (2003-2014) or a single infusion of 
infliximab at 5mg/kg (2001-2014).  Choice of rescue therapy was determined by the patient after 
being presented with an evidence based overview of the risks and benefits of the available options 
of infliximab and ciclosporin. The treating physician did not suggest a particular rescue therapy 
based on the severity of the case. Patients who failed medical rescue therapy or developed 
complications of severe colitis (perforation, toxic megacolon, haemorrhage or multiple organ 
dysfunction) at any stage during their admission were referred for emergent colectomy. (Figure 2) 
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Data Collection 
 
All data were prospectively collected and entered into our secure inflammatory bowel disease 
database.  In the case of patients transferred for care from a regional hospital all relevant clinical 
and laboratory data were requested at the time of admission to our metropolitan hospital and entered 
at that time point.  
Clinical and laboratory parameters were assessed in a binary manner, using previously published 
thresholds in comparable cohorts of ASUC patients, with a 0 referring to low risk, and 1 referring to 
high risk.  Abdominal radiographic colonic diameter was defined as abnormal in this study as ≥ 
5.5cm as this has been demonstrated in prior studies to correlate with medical therapy failure and 
colectomy.
35, 44
 CRP on day 3 of ≥ 45 mg/L was chosen as a cut-off as it is the key component of 
both the Oxford and Swedish adult indexes for predicting colectomy.
11, 38, 45
 The same cut-off was 
used in evaluating CRP on day 1 in this study for consistency.  
Number of bowel actions ≥ 8 on day 3 has been strongly correlated with medical therapy failure and 
colectomy in multiple adult and a paediatric study.
11, 38, 45
 Cut-offs for haemoglobin on admission (< 
105 g/L) and ESR on admission  (≥ 31 mm/hr) were chosen as they are components of the Truelove 
and Witts’ criteria and have been shown to increase the colectomy rate if present on admission10. 
The cut-off for albumin on admission was chosen as < 30 g/L as it has been associated with 
intravenous steroid failure in previous studies.
35, 44
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Data Analysis 
 
Demographic and clinical parameters of the cohort were compared between those who either had or 
did not have a colectomy at the 30-day endpoint. Age at the time of admission was compared using 
the independent samples t-test, disease duration was compared using the Mann Whitney U test, 
while all other parameters were compared using the Chi-Square test. Odds ratios (95% confidence 
intervals (95% CI) are presented to define effect sizes and estimated error for each parameter to 
predict outcome. Multivariate analyses were conducted using the stepAIC function with the 
Generalised Linear Model (binomial GLM) to ascertain the optimum combination of parameters 
associated with colectomy. Bonferroni correction was applied to the comparative alpha value, such 
that P values were compared to an adjusted alpha ( = 0.05/ K (K = number of characteristics 
tested), 0.05/18 = 0.00278).  
 
Assessing all possible parameters, (demographic, clinical and laboratory) in the multivariate setting 
using the stepAIC function (the stepAIC function reduces the model parameter space sequentially 
via optimal Akaike information criterion (AIC) assessment), seven parameters were chosen linearly 
associated with colectomy (Table 2). While not all parameters have p-values less than the nominal 
levels of significance, each contribute to the likelihood of having a colectomy by the 30-day 
endpoint. All statistical analyses were conducted using the R statistical environment version 3.2.3 
33
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Results 
 
Patient cohort 
 
A total of 225 index admissions of ASUC were identified from January 2000 to May 2014.  
Comprehensive review of the cases resulted in 200 patients who met the inclusion criteria (89 % of 
the cohort).  Of these 131 (65.5 %) presented directly to the RBWH and 69 (34.5 %) were 
transferred for care after initial management in a regional hospital.  
 
Overall 62 patients failed medical therapy and went on to colectomy within 30 days of admission 
(31 %). Twenty-two patients proceeded directly to colectomy after failing intravenous steroids 
(22%). Rescue therapy was administered to 113 patients (51 %) who failed intravenous steroids 
during the initial severe episode.  Forty-six patients received ciclosporin (41%) and 67 received 
infliximab (59 %).  
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Univariate and multivariate analysis of clinical, radiographic and laboratory parameters 
 
Results for the univariate analyses of demographic, clinical, radiographic and laboratory parameters 
are shown in Table 1. There was no significant difference in the mean age or median disease 
duration for those patients who had a colectomy as compared with those that did not (P = 0.093 and 
0.108 respectively). There were slightly more females in the colectomy group (P = 0.031) and those 
that were ex-smokers were marginally less likely to have colectomy (P = 0.047).  
For the clinical characteristics there were higher rates of colectomy for those patients with ≥ 8 
bowel actions on day 3 (P = 0.0006), first presentation of UC (P = 0.001) and transfer from a 
regional hospital (P = 0.0006) which remained significant post adjustment for multiple 
comparisons.  Extensive disease distribution was not significant post adjustment for multiple 
comparisons (P = 0.009). Those who were on an immunomodulator or oral steroid at the time of 
admission with ASUC were at no increased risk for colectomy (immunomodulator P = 0.422), oral 
steroids P = 0.555).   Abdominal radiograph colonic diameter of ≥ 5.5cm remained predictive of 
colectomy post-adjustment for multiple comparisons (P = 0.0004) 
Of the laboratory parameters, only bowel actions ≥ 8 per day and CRP ≥ 45 mg/L on day 3 (P = 
0.001) remained significant post adjustment for multiple comparisons. Erythrocyte sedimentation 
rate (ESR) (P = 0.034) and albumin (P = 0.04) levels at day 1 although not significant post 
adjustment for multiple comparisons, were still moderately associated with colectomy at the 
nominal significance level.  
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Discussion 
 
In our study we assessed the effect of immunosuppression prior to hospitalization on the outcome of 
ASUC in the largest cohort of patients to date examined in this regard.  In reviewing 200 
consecutive ASUC patients admitted over a 14-year period we have demonstrated that 
immunosuppressive use prior to admission does not significantly increase the risk of colectomy.    
 
Selected patient-related parameters however were most important in determining their likelihood of 
medical therapy failure and colectomy. Our study demonstrates no significant association between 
immunosuppression with oral steroid or immunomodulator therapy prior to admission and risk of 
colectomy.  A single retrospective study reported that in intravenous steroid-refractory moderate-
severe ulcerative colitis patients, prior oral steroid use existed in 70 % of patients undergoing 
colectomy compared with 42 % who avoided colectomy.
38
  Consistent with our findings when 
further analysis was performed in that study, oral steroid use prior to admission was not a predictor 
of colectomy whereas the number of bowel actions and CRP level on day 3 were predictive of 
colectomy at 30 days.
38
  
 
There is a paucity of published data examining the effect of immunomodulator therapy on the 
ASUC population overall with little to guide clinical management of patients established on these 
medications at time of presentation. This is likely due to the small numbers of patients on this 
treatment (8%) who subsequently develop ASUC and is a testament to its protective effects.
35
 
Multiple studies including two controlled trials have shown that treatment with these agents can 
reduce or eliminate steroid use over time and maintain long term steroid free remission. 
16-20
    The 
immunomodulator azathioprine used in combination with infliximab therapy in moderate-severe 
ulcerative colitis outpatients has also been demonstrated to increase clinical remission, clinical 
response and mucosal healing when compared with infliximab or thiopurine monotherapy.
21
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Although no studies have looked at an entire cohort of ASUC patients to determine the effect of 
immunosupressive treatment, studies have investigated the effect of prior immunomodulator use on 
the outcome of intravenous steroid-refractory patients receiving rescue therapy.  In these studies, 
sub-analysis with small numbers all showed no significant increase in colectomy rate when 
infliximab was used as rescue therapy.  
22-24
  When looking at ciclosporin treated patients two sub-
analyses including one study with prospective data showed no significant increase in colectomy rate 
in patients already established on an immunomodulator (azathioprine) compared with 
immunomodulator-naïve patients.
39
 
24
  
 
There is a single study demonstrating a higher colectomy rate in patients established on 
immunomodulator therapy prior to an ASUC episode requiring rescue therapy. A large 
retrospective study by Moskovitz et al. found patients receiving ciclosporin rescue therapy 
demonstrated a higher 1-year colectomy rate if already on an immunomodulator (azathioprine) (59 
%) compared to those starting azathioprine de novo at the time of rescue therapy (35 %). 
25
  Our 
results differ from the Moskovitz et al. study and agree with the majority of published literature.
22-
24, 39
 The Moskovitz et al study gives valuable insights into the use of ciclosporin for this indication, 
however we notice that several potential confounders were not addressed in their comparison of 
immunomodulator experienced and de novo patients.
25
  These include the presence or absence of 
abdominal radiographic colonic dilation, bowel frequency on day 3 and CRP level on day 3, all of 
which are strong predictors of colectomy and would likely have influenced the outcome more so 
than treatment with an immunomodulator.   
 
In our study results from multiple logistic regression analysis confirmed several key parameters 
which can stratify a patient as high risk for colectomy at 30 days post-admission. Abdominal 
radiographic colonic dilation ≥ 5.5 cm, transfer from a regional hospital, CRP > 45 mg/L on day 3, 
first presentation of UC and bowel frequency of ≥ 8 on day 3 of treatment predicted the need for 
colectomy post-index ASUC episode. Abdominal radiographic colonic dilation, bowel frequency ≥ 
8 on day 3 and CRP ≥ 45 mg/L on day 3 of treatment successfully replicate the findings of previous 
studies of colectomy predictors in ASUC.
35, 38, 44, 45
 A trend towards lower colectomy rates were 
seen in patients on an oral 5-ASA at the time of admission compared to those who were not (23.7 % 
vs. 36.1 p = 0.06).  
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Patients admitted to hospital with ASUC as their first presentation of ulcerative colitis were at 
higher risk for colectomy than those admitted with a severe flare of established disease in our 
cohort.  First presentation with ASUC was seen in 25 % of our cohort which is marginally lower 
than the 34-48 % described in similarly defined cohorts 
10, 11, 35
 Our results differ from previous 
studies of similar cohorts in the modern era that show no significant increase risk of colectomy 
during the first presentation of UC.
7, 10, 35
  We postulate this may be due to diagnostic and treatment 
delays in patients presenting to our regional referring hospitals (all with no gastroenterologist 
during the study period) leading to a prolonged bout of colitis, which may adversely affect rescue 
with medical therapy. 
 
There are several limitations to this study. Firstly this is a real life study and therefore the patients 
could not be randomized into the various immunosuppressive treatment groups prior to admission.  
This introduces the possibility of selection bias as the more unwell patients potentially end up on 
immunosuppression. Also no formal matching was attempted between the naïve and treated patient 
groups introducing the possibility of selection bias in this cohort of patients which is a limitation of 
observational studies.  There is also the possibility that the sample size was inadequate to detect a 
difference in colectomy rate between the different treatment regimes.  As a real life cohort we had 
no capacity to increase the number of patients studied.    
 
The results of this study demonstrate that immunosuppressive use prior to admission with ASUC 
does not increase the risk of colectomy and cannot reliably identify patients at higher risk for 
medical therapy failure.  Patients with the following key parameters:  abdominal radiographic 
colonic dilation ≥ 5.5cm, transfer from a regional hospital, CRP ≥ 45 mg/L on day 3, first 
presentation of ulcerative colitis or a bowel frequency ≥ 8 per day on day 3, should be considered 
high risk for colectomy and have rescue therapy discussed and given early along with stomal 
therapist and colorectal surgery consultation.   
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Table 1:  Baseline demographics and univariate analysis 
Characteristic No colectomy  Colectomy OR (95%CI) p-value 
N 138 62   
Age     
     Mean +/- SD 36.24 (16.56) 40.45 (16.17)  0.093 
Gender     
     Male 74 23 ref (1.0)  
     Female 64 39 1.95 (1.06 - 3.65) 0.0306 
Smoking status     
    Never 88 28 ref (1.0)  
    Ex 42 28 0.48 (0.25 - 0.91) 
    Current 8 6 0.42 (0.14 - 1.33) 0.047 
Disease duration (Years)     
     Median (IQR) 2 (7.3) 1 (3.5)  0.108 
Disease extent     
     E1/E2 52 12 ref (1.0)  
     E3 85 50 2.52 (1.25 - 5.38) 0.0093 
Abdominal radiograph colonic diameter    
     < 5.5cm 129 47 ref (1.0)  
     ≥ 5.5cm 9 15 4.51 (1.86 - 11.52) 0.0004 
First presentation of UC     
     No 112 37 ref (1.0)  
     Yes 26 25 2.89 (1.49 - 5.66) 0.0013 
Origin of initial presentation     
     Metropolitan hospital (RBWH) 101 30 ref (1.0)  
     Regional hospital (All sites) 37 32 2.89 (1.55 - 5.45) 0.0006 
5-ASA on admission     
     No 76 43 ref (1.0)  
     Yes 61 19 0.55 (0.29 - 1.04) 0.0644 
Oral steroid on admission     
     No 73 30 ref (1.0)  
     Yes 65 32 1.2 (0.65 - 2.19) 0.555 
Immunomodulator on admission     
     No 97 47 ref (1.0)  
     Yes 41 15 0.76 (0.37 - 1.49) 0.422 
Bowel actions on Day 1     
     6-7 31 8 ref (1.0)  
     ≥ 8 107 54 1.93 (0.86 - 4.8) 0.1145 
 
Bowel actions on Day 3     
     < 8 102 31 ref (1.0)  
     ≥ 8 33 30 2.97 (1.57 - 5.67) 0.0006 
CRP on Day 1     
     < 45 mg/L 63 21 ref (1.0)  
     ≥ 45 mg/L 73 40 1.64 (0.88 - 3.11) 0.1185 
CRP on Day 3     
     < 45 mg/L 109 35 ref (1.0)  
     ≥ 45 mg/L 28 26 2.87 (1.49 - 5.58) 0.0012 
ESR on Day 1     
     < 31 mm/hr 30 6 ref (1.0)  
     ≥ 31 mm/hr 73 40 2.68 (1.08 - 7.73) 0.0341 
 
Albumin Day 1     
      ≥ 30 g/L 86 29 ref (1.0)  
      < 30 g/L 52 33 1.87 (1.02 - 3.46) 0.0397 
Haemoglobin on Day 1     
     ≥ 105 g/L 101 45 ref (1.0)  
     < 105 g/L 37 17 0.97 (0.49 - 1.90) 0.9666 
36 
 
Table 2:  Multivariate analysis of variables associated with colectomy 
 
Characteristic OR (95%CI) p-
value 
Abdominal radiograph colonic diameter        
     < 5.5cm ref (1.0)  
     ≥ 5.5cm 4.0 (1.46 - 
10.96) 
0.007 
Origin        
     Metropolitan hospital (RBWH) ref (1.0)  
     Regional hospital (All sites) 2.39 (1.18 - 
4.83) 
0.016 
CRP on Day 3        
     < 45 mg/L ref (1.0)  
     ≥ 45 mg/L 2.41 (1.15 - 
5.08) 
0.02 
First presentation of UC        
     No ref (1.0)  
     Yes 2.21 (1.05 - 
4.68) 
0.037 
Bowel actions on Day 3        
     < 8 ref (1.0)  
     ≥ 8 2.1 (1.03 - 4.29) 0.041 
        
Age at presentation      1.02 (1 - 1.04) 0.084 
        
Disease Extent        
     E1/E2 ref (1.0)  
     E3 2.26 (1 - 5.11) 0.051 
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Manuscript (Aim 2): Regional transfer patients are three times as likely to 
undergo colectomy compared with metropolitan patients with acute severe 
ulcerative colitis 
 
Significance of this study 
 
What is already known on this subject? 
 
 Patients are commonly transferred from regional hospitals with acute severe ulcerative 
colitis (ASUC) not responding to medical therapy for further management. A higher 
mortality and rate of peri-operative complications has been demonstrated in regionally 
managed ASUC in the literature but no data on colectomy rates. 
 
What are the new findings? 
 
 Patients transferred from a regional hospital have three times the risk of colectomy at 30 
days post admission compared with metropolitan presenting patients with ASUC 
 
 Intravenous steroid failure is high in the regional transfer cohort of patients compared with 
metropolitan presenting patients. Regional transfer patients with ASUC are more likely to 
have significant hypoalbuminemia,  be first presentations of ulcerative colitis, have a shorter 
disease duration and more extensive disease distribution 
 
 Bowel frequency ≥ 8 on day 3 and CRP ≥ 45 mg/L on day 3 are confirmed to predict 
colectomy in this high risk group of regional transfer patients with ASUC 
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How might it impact on clinical practice in the foreseeable future? 
 
 Patients with either a UC flare or a new presentation admitted to regional hospitals without a 
gastroenterologist should be discussed with the nearest specialist IBD unit within the first 24 
hours of admission. This allows for risk stratification and management according to an 
evidence-based algorithm with high risk patients receiving earlier specialized and more 
intensive treatment to improve their outcomes.  
 
 Following case discussion with an IBD centre, regional hospital patients satisfying the 
criteria for an acute, severe attack should be promptly transferred to the nearest tertiary 
hospital with an IBD and colorectal surgical team, for intensive medical therapy, which may 
include rescue therapy and/or surgery.   
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Abstract 
 
Background and aims:  Patients are commonly transferred from regional to metropolitan hospitals 
with acute severe ulcerative colitis (ASUC) not responding to initial medical management for 
further care. We aimed to compare the colectomy rates and baseline characteristics of ASUC 
patients presenting directly to the front door of our metropolitan hospital versus patients transferred 
in from regional hospitals.   
 
Method:  An observational cohort study was conducted in a tertiary referral metropolitan hospital to 
examine the 30 day colectomy rate in metropolitan versus regional transfer patients using 
prospectively collected data on 200 consecutive index ASUC patients meeting Truelove and Witts 
criteria.  
 
Results:  The 30 day colectomy rate was 46.4 % (32/69) in regional transfer patients compared with 
22.9 % (30/131) in metropolitan presenting patients (p = 0.0006).  Complete intravenous steroid 
response was seen in 21.7 % (15/69) of regional transfer patients versus 42 % (55/131) (p = 0.004) 
in metropolitan presenting patients.   There was trend towards poorer rescue therapy success at 30 
days in regional transfer patients 55 % (25/45) compared with metropolitan patients 71 % (47/66) (p 
= 0.069).  Predictors of high risk of colectomy in regional transfer patients were bowel actions ≥ 8 
per day on day 3 (p = 0.003) and CRP ≥ 45 mg/L on day 3 (p = 0.003).  
 
Conclusion:  Regional transfer patients have a three-fold increased risk of colectomy at 30 days 
compared with metropolitan patients, driven by more severe disease and hence a lower intravenous 
steroid and rescue therapy response.  An agreed model of care for regional ASUC patients between 
regional and metropolitan centers, including day 1 communication, appropriate patient transfer, and 
early intensive, multidisciplinary care in a metropolitan center, may improve the outcomes for these 
patients. 
 
Keywords: Regional; Rescue therapy; Ulcerative colitis; Colectomy                       
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Introduction 
Acute severe ulcerative colitis (ASUC) is a major, potentially life-threatening complication of 
inflammatory bowel disease (IBD). The overall response to intravenous corticosteroid therapy has 
plateaued at between 60 and 70%
1
, while the colectomy rate in this severe subgroup is between 30 
and 40%
2,3
. Mortality is 1-3% across all types of hospitals, significantly driven by older age at 
presentation
4
. The availability of rescue therapy with either ciclosporin or infliximab has reduced 
the short-term colectomy rate, but long term results are less impressive 
5,6
.   
Many incident and prevalent IBD patients live in regional or rural areas and those who develop 
severe symptoms may present to their local hospitals for initial assessment and investigation. A 
proportion of these are transferred to a metropolitan tertiary hospital for specialized, intensive care 
but their outcomes are not described in the literature. Many regional and rural hospitals lack a 
gastroenterologist and hence are not familiar with the highly specialized care required for patients 
with ASUC.
46
 The impact of this lack of direct access to specialized IBD care is currently not 
known specifically with respect to the outcomes of ASUC patients presenting to regional and rural 
hospitals.  
Higher mortality has been demonstrated in the past with case series from regional hospitals 
managing ASUC in the United Kingdom as high as 24 %. 
5, 30, 34
  There are also data from the 
United States demonstrating higher post-operative mortality and morbidity for patients having 
colectomy for ulcerative colitis performed in low volume surgical centers.
5, 31
 Significantly different 
colectomy rates for hospitalized ulcerative colitis patients in the United States have been 
demonstrated in regional and rural patients depending on their geographic location, insurance status, 
ethnicity and hospital type.
32
   
 
This raises the question:  Does where a patient lives affect their access to appropriate care and their 
eventual outcome if they present with ASUC? Our inflammatory bowel disease unit, like many 
around the world, strongly encourages the referral of all IBD patients living in regional and rural 
areas where there is no direct access to specialized IBD and surgical care.   
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Regional and rural disparity in patient outcomes has been well demonstrated in a number of non-
gastrointestinal chronic diseases including asthma, chronic obstructive pulmonary disease, 
myocardial infarction and cancer related deaths of all types.
27-29
  Given the vast geographic 
distances in regional and rural Australia as in many countries across the world, residential location 
may be a major factor in ASUC patients gaining access to appropriate and timely medical therapy 
leading to potentially avoidable colectomies. Many regional and rural UC patients have no local 
access to a gastroenterologist which may result in delayed recognition of the condition, delayed 
identification of a severe episode and delayed initiation of optimal therapy, all of which impact on 
outcome.1  In Australia this issue is of particular relevance as under our pharmaceutical benefits 
scheme a gastroenterologist or consultant physician specializing in gastroenterology is required to 
prescribe rescue therapy with a biologic agent. 
 
No studies to date have compared the colectomy rate in patients presenting with ASUC and living 
in a regional or rural area as compared to those living in a metropolitan area. To address this and 
identify any modifiable factors to improve outcome, we performed a retrospective observational 
cohort study using prospectively collected data to: 1. evaluate the colectomy rates of our regional 
transfer versus metropolitan patients with ASUC and 2. Identify any modifiable factors to improve 
outcome.        
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Methods 
 
Sample selection and observations 
A retrospective observational cohort study was conducted using prospectively collected data on 
ASUC patients admitted directly to the Royal Brisbane and Women’s hospital (RBWH) 
(Metropolitan) or transferred from a regional hospital (Regional transfer – all sites) from January 
2000 – May 2014. Conduct of this study was approved by the RBWH ethics Committee.  All 
patients provided written informed consent.  All subjects were followed by clinical outpatient 
review from admission until 30 days post admission by which time they either had a colectomy or 
were censored.  
 
Definitions 
 
Metropolitan patient (RBWH)  
 
Metropolitan patients were defined as those presenting directly to the front door of the RBWH, an 
academic teaching secondary and tertiary hospital located in the metropolitan area of a capital city 
(Brisbane, Australia) with an inflammatory bowel disease team managing the inpatient admissions.   
 
Regional transfer patient (Regional transfer – All sites) 
 
Regional transfer patients formed a cohort of patients consisting of patients transferred from one of 
ten regional hospitals without a gastroenterologist outside the metropolitan area of our capital city 
(Brisbane, Australia). Our estimated referral area covers 550,000 square kilometers with a 
combined population of 1.4 million people.
47
 The median distance from the regional referring 
hospitals(Regional transfer – All sites) to the RBWH (Metropolitan) was 255.1 km (IQR 47.0 – 
435.9 km).
48
 Regional patients were admitted and managed under the general medical or surgical 
inpatient teams during their initial admission prior to transfer to our tertiary hospital. 
46 
 
 
 
Acute severe ulcerative colitis 
 
Ulcerative colitis cases were confirmed on the basis of consistent clinical, biochemical and 
histologic features as per the Lennard Jones criteria.
49
 ASUC was defined as having satisfied 
Truelove and Witts criteria of ≥ 6 bloody bowel actions per day and at least one of the following 
features of systemic toxicity:  Temperature > 37.8 °C, Tachycardia > 90 beats/minute, Haemoglobin 
< 105 g/L or Erythrocyte sedimentation rate (ESR) > 30 mm/hr.
40
  All cases had confirmed 
significant colonic inflammation based on endoscopic mayo score ≥ 2 on admission flexible 
sigmoidoscopy. 
 
Response to treatment 
 
Complete intravenous steroid response was defined as < 4 bowel actions on day 3 of intravenous 
steroid treatment without blood.  Patients with > 4 bowel actions on day 3 or less than 4 bowel 
actions but persistent blood in the stool were considered incomplete intravenous steroid responders.   
Rescue therapy success was defined as avoidance of colectomy. 
 
Management 
Patients once admitted to our metropolitan hospital were managed according to our department 
protocol for managing ASUC.
43
  Metropolitan patients and regional patients once transferred 
received close electrolyte monitoring and replacement to maintain values in the normal range.  
Thromboembolic prophylaxis with subcutaneous heparin was used in all cases.  Second daily 
abdominal radiographs were obtained and maximal colonic diameter recorded.  Patients who had an 
incomplete intravenous steroid response after three days of hydrocortisone therapy at RBWH were 
offered rescue therapy with ciclosporin or infliximab.  Patients selected rescue therapy after being 
presented with an evidence based overview of the two therapies providing explanation of the 
potential risks and benefits of the therapies.   Patients who failed rescue therapy or developed 
complications of severe colitis such as toxic megacolon, perforation, colonic haemorrhage or multi-
organ dysfunction were referred for emergent colectomy.  
47 
 
Outcomes 
 
Colectomy rates at 30 days post admission were evaluated in the two cohorts of patients (Regional 
transfer and metropolitan).  Intravenous steroid response on day 3 of the index hospital admission 
was evaluated. Rescue therapy success at 30 days post admission in cases of intravenous steroid 
failure was also evaluated.  
 
 
Statistical methodology 
 
Demographic, radiographic and clinical parameters were assessed between metropolitan and 
regional transfer cohorts. Laboratory and clinical parameters including bowel actions, C-reactive 
protein (CRP), erythrocyte sedimentation rate (ESR), albumin and haemoglobin were assessed 
between colectomy / no colectomy at 30 days, stratified by whether patients initially presented to a 
metropolitan or regional hospital. Quantitative parameters were assessed either via the independent 
samples t-test or the Mann Whitney U test, while categorical factors were assessed with the Chi 
square test. Laboratory parameters were transformed into binary factors based upon previously 
defined thresholds. All statistical analyses were performed using the R statistical environment 
(version 3.2.3).
33
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Results 
A total of 225 patients with an index admission with ASUC were identified between January 2000 
and May 2014.  Of these 200 patients met the inclusion criteria and were included in the study. 
(Figure 1)  One hundred and thirty-one patients had presented directly to our metropolitan hospital 
(65.5%) and 69 were transferred after initial assessment in a regional hospital (34.5%). 
 
The regional cohort included a greater number of incident cases of UC and thus a shorter disease 
duration as compared to the metropolitan cohort. Regional patients also demonstrated more 
extensive disease as compared to metropolitan patients. (Table 2) Regional patients were three 
times as likely to have significant hypoalbuminemia (≤ 30 mg/L) at baseline as compared with 
metropolitan patients (p = 0.0001). There was no significant difference in immunosuppressive 
treatment prior to admission between the two cohorts (oral steroids: p = 0.29, immunomodulator: p 
= 0.27).  There was no significant difference in the median number of Truelove and Witt criteria on 
admission between the two cohorts at 2.0 (p = 0.844). 
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Clinical outcomes 
Colectomy rate 
The 30 day colectomy rate was significantly higher in regional patients as compared with 
metropolitan patients (46.4 % vs. 22.9% p = 0.0006). Bowel frequency ≥ 8 per day on day 3 (p = 
0.003) and CRP ≥ 45 mg/L on day 3 (p = 0.003) were associated with risk of colectomy at 30 days. 
(Table 3) There was no statistically significant difference in the proportion of patients from each 
cohort who went directly to early colectomy after failing intravenous steroids and without receiving 
rescue therapy as a consequence of fulminant colitis or development of complications (metropolitan 
: n =11, regional transfer : n = 11,  p = 0.105). 
 
Intravenous steroid response 
Regional patients were less likely to make a complete response to intravenous steroids (21.7%) as 
compared to metropolitan patients (42.0%) (p = 0.004). Across the two cohorts, regional patients 
received a longer total course of intravenous steroids as compared to metropolitan patients: 8.0 days 
versus 6.0 days respectively (p = 0.001). Regional patients spent a median of 5.0 days in their 
regional hospital prior to transfer to our metropolitan hospital. 
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Rescue therapy  
Of the 200 patients included in this study 111 (55.5%) received rescue therapy with infliximab or 
ciclosporin after failing to respond to intravenous steroids.  Regional patients required rescue 
therapy more frequently as compared with metropolitan patients: 65.2 % versus 50.4 % (OR: 1.85 
(1.01-3.37) p = 0.045).  No regional patients received rescue therapy prior to transfer to our 
metropolitan hospital due to the lack of a gastroenterology service required to prescribe and monitor 
the therapy. There was no significant difference in median number of days on intravenous steroids 
prior to commencing rescue therapy in the regional transfer versus metropolitan cohorts at 5.0 vs. 
5.0 days (p = 0.22)  
 
To further investigate the characteristics of patients requiring rescue therapy, we ran additional 
analyses comparing the demographic, clinical and biochemical parameters of this severe subgroup 
within both cohorts.  Regional patients had shorter disease duration and a more extensive disease 
distribution as compared to metropolitan patients, consistent with the pattern seen in the overall 
cohort.  There was no significant difference in age, gender, smoking status, inflammatory markers, 
colonic dilatation, or number of Truelove and Witts criteria met on admission between the two 
cohorts requiring rescue therapy.  (Supplementary table 1) Regional patients demonstrated a lower 
response rate to rescue therapy at 30 days as compared to metropolitan patients (55 % versus 71 %) 
(p = 0.069).   
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Discussion 
 
In this study, we assessed the 30-day colectomy rate in regional transfer and metropolitan patients 
who present with an attack of ASUC. We have demonstrated for the first time that those patients 
who initially present to a regional hospital requiring transfer have a three times increased risk of 
colectomy at 30 days compared with those presenting directly to a metropolitan hospital. Regional 
patients were more than twice as likely to fail intravenous steroids as compared to metropolitan 
patients. Parameters predictive of colectomy in regional patients were bowel frequency ≥ 8 and 
CRP ≥ 45 mg/L on day 3 of therapy.  Regional patients with these features were almost five times 
more likely to undergo colectomy at 30 days as compared to those with a bowel frequency < 8 per 
day and CRP < 45 mg/L. 
  
The primary factor identified for the higher colectomy rate in regional patients was poor response to 
intravenous steroids. This is likely because these patients are a selected group of non-responders to 
initial therapy which in essence marks them as high risk for colectomy.  The complete intravenous 
steroid response rate in regional patients was very low at 21.7 % as compared with the metropolitan 
cohort response rate of 42 %.  Response to intravenous steroids has been identified as the primary 
factor in avoiding colectomy in patients presenting with ASUC across multiple studies. 
36, 50-52
 From 
the literature the response to intravenous steroids is 60-70 % but the figures in individual cohorts 
vary widely due to heterogeneity in definitions of steroid failure, severity of colitis and treatment 
regimes.
2, 53, 54
  
 
There are a number of factors that may have contributed to this poor steroid response rate in 
regional patients. These include hypoalbuminemia, disease extent, disease duration and fraction of 
incident cases of ASUC.  
52 
 
 
 
 
Regional patients were three times as likely to have significant hypoalbuminemia on admission (< 
30 g/L) compared to metropolitan presenting patients (OR 3.16 : p = 0.0001). Hypoalbuminemia 
has been demonstrated to predict failure or slow response to intravenous steroids in cohorts of 
ASUC.
35, 45, 50
 Previous studies have demonstrated that a serum albumin of < 30 g/L on day 1 
predicts intravenous steroid therapy failure on day 3 of treatment.
35, 44
 Hypoalbuminemia has also 
been demonstrated to predict infliximab rescue therapy failure due to a significant loss of the drug 
due to protein losing enteropathy and colopathy in an extensively ulcerated colon.
55
  
This may in part explain the trend towards poorer success of rescue therapy seen in our regional 
transfer cohort of patients compared to our metropolitan presenting patients.  Hypoalbuminemia in 
acute illness is a poor prognostic marker of outcome and unlikely causative in itself.  In a meta-
analysis of 90 cohort studies in a wide variety of non-gastrointestinal diseases hypoalbuminemia 
was associated with increased morbidity, mortality, length of stay and resource utilization.
56
    
Regional patients had a higher frequency of extensive disease distribution as compared to 
metropolitan patients. Extensive disease is correlated with a higher risk of colectomy.
10
  Patients 
with an attack of ASUC and extensive disease are three times more likely to come to colectomy as 
compared to those with left sided disease or proctitis. 
10, 57
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We saw a significantly higher proportion of incident ASUC in our regional cohort as compared with 
the metropolitan cohort (37.7 % versus 19.0 %: OR 2.55, p = 0.0041). The rate of incident ASUC 
across all cases in published cohorts is between 34 and 48 %.
10, 11, 35
  The rate of incident ASUC 
was significantly lower in our metropolitan cohort which is likely due to our metropolitan hospital 
having a larger proportion of existing IBD patients in regular specialist follow-up as opposed to 
regional hospitals without access to a gastroenterology service where a higher proportion of 
hospitalized patients will be first presentations of UC.   These differences in disease characteristics 
were consistent with findings in our subgroup analysis of patients receiving rescue therapy. 
(Supplementary table 1)  
 
The majority of intravenous steroid non-responders in both cohorts received rescue therapy with 
either ciclosporin or infliximab. Regional patients were more likely to require rescue therapy as 
compared to metropolitan patients (p = 0.045).    Response to rescue therapy at 30 days was lower 
in regional patients compared with metropolitan patients (55 % vs 71 %) (p = 0.069). The response 
rate in metropolitan patients is consistent with published short term response rates for ciclosporin 
(64-91%) and for infliximab (61-85 %).
58
  Regional patients had a lower than expected rescue 
therapy response rate. Factors contributing to a poor steroid response, described above, are likely to 
have contributed to this poor response to rescue therapy.  
The timing of rescue therapy administration is an important factor in the management of ASUC. 
Regional patients in our study received rescue therapy at a median of day 6 of intravenous steroids, 
similar to metropolitan patients (p=0.22).  However, patients with high risk features including 
hypoalbuminemia, extensive disease, and incident status, are likely to benefit from earlier rescue 
therapy, specifically day 3.  
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Factors predicting colectomy in our regional patients were limited to bowel frequency of ≥ 8 per 
day and CRP   45 ≥ mg/L on day three of intravenous steroid treatment. Regional patients with 
these features were almost five times more likely to undergo colectomy at 30 days than those with a 
bowel frequency < 8 per day and CRP < 45 mg/L.  Although these parameters are established 
predictors of outcome in patients with ASUC, this is the first study to replicate these observations in 
a regional transfer cohort of patients. 
38, 44, 45
 
 
This study was conducted in a major metropolitan referral hospital that provides specialist IBD care 
to a group of smaller regional hospitals without dedicated gastroenterology services. The results 
demonstrate significant differences in disease characteristics and treatment outcomes for ASUC in 
regional patients as compared to metropolitan patients. Potential weaknesses of the study include its 
retrospective analysis of a prospectively-collected cohort and the inclusion of only one referral 
center. Strengths of the study include the prospective collection of data on all cases of acute colitis 
managed at the RBWH and the role of this hospital as the only referral center for regional and rural 
hospitals in the region.   
Patients requiring transfer from a regional hospital have already identified themselves as high risk 
for colectomy as they have failed initial treatment but until now the magnitude of that risk was 
unknown.  Whilst their initial non-response to intravenous steroids confers them significant risk for 
colectomy it is not clear from the available data what other factors including management protocols 
at regional hospitals, delay to optimal treatment and delay to diagnosis have on the colectomy rate.  
This is an important avenue for further study but unfortunately reliable data on the pre-admission 
management of patients with ASUC is scant as investigations are performed by their general 
practioner and through emergency department visits. 
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The results of this study have implications for clinical practice.  Patients with an acute severe colitis 
presenting to a regional hospital without a dedicated gastroenterology service are a very high risk 
group of patients. Thus, a combination of early recognition of the diagnosis, communication with 
the nearest IBD centre, and transfer for intensive medical (and colorectal surgical treatment if 
necessary) therapy is essential.  
This will provide patients with access to optimized, evidenced-based care within a “high-volume” 
hospital environment and minimize any variance in care. At a broader level, however, our study 
illustrates some of the challenges faced by individuals living in regional and rural areas as 
compared to those who choose to live in metropolitan areas. The lack of rapid access to specialist 
services within regional and rural areas is likely to have contributed to some of the differences in 
baseline disease characteristics identified in this study, including the frequency of extensive disease, 
hypoalbuminemia and incident ASUC. All these point to potential delays in diagnosis in the 
regional and rural settings. Lack of specialist services in these areas has long been recognized both 
within Australia and the United States.  
 
In summary, patients with UC living in regional and rural areas of Queensland, Australia, who 
present to their local hospital with ASUC have a significantly higher risk of colectomy at 30 days as 
compared to those who present to a metropolitan hospital with a dedicated IBD team. Regional 
ASUC patients have a number of high risk features contributing to these poorer outcomes including 
higher rates of extensive disease, hypoalbuminemia, and incident ASUC.  
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Table 1: Treatment outcomes 
 
Characteristic Metropolitan Regional 
tratra 
 
 tra 
 
OR (95%CI) p-
value 
Complete IV steroid response (day 
3) 
         No 76 54 ref (1.0) 
      Yes 55 15 2.61 (1.33 – 
5.09) 
0.0043 
Direct to colectomy after IV 
steroids 
         No 120 58 ref (1.0) 
      Yes 11 11 0.48 (0.20 – 
1.18) 
0.105 
Received rescue therapy  
         No 65 24 ref (1.0) 
      Yes 66 45 1.85 (1.01 – 
3.37) 
0.0448 
Rescue therapy success at 30 days 
         No 18 20 ref (1.0) 
      Yes 47 25 2.09 (0.94 – 
4.65) 
0.0693 
Colectomy at 30 days   
        No 101 37 ref (1.0) 
      Yes 30 32 2.91 (1.56 – 
5.44) 
0.0006 
 
 
 
  
58 
 
Table 2:  Univariate analysis of demographic and clinical parameters   
 
Characteristic Metro Region
al 
OR (95%CI) p-value 
N 131 69 
  Age 
         Mean +/- SD 37.75 
(16.86) 
37.16 
(15.96) 
 
0.808 
Gender 
         Male  2  ref (1.0) 
      Female 63 40 1.48 (0.82 - 2.7) 0.1839 
Smoking status 
        Never 79 37 ref (1.0) 
     Ex 40 30 0.62 (0.34 - 1.15) 0.131 
    Current 12 2 2.81 (0.6 - 13.2) 0.174 
Disease duration (Years) 
         Median (IQR) 2 (8.77) 1 (2.81) 
 
0.006 
Disease extent 
         E1/E2 49 15 ref (1.0) 
      E3 81 54 2.16 (1.12 - 4.36) 0.0218 
Abdominal radiograph colonic diameter 
        < 5.5cm 116 60 ref (1.0) 
      ≥ 5.5cm 15 9 1.17 (0.46 - 2.8) 0.7417 
First presentation of UC 
         No 106 43 ref (1.0) 
      Yes 25 26 2.55 (1.32 - 4.94) 0.0041 
5-ASA on admission 
         No 72 47 ref (1.0) 
      Yes 58 22 0.58 (0.31 - 1.07) 0.0813 
Oral steroid on admission 
         No 71 32 ref (1.0) 
      Yes 60 37 1.37 (0.76 - 2.47) 0.2927 
Immunomodulator on admission 
         No 91 53 ref (1.0) 
      Yes 40 16 0.69 (0.34 - 1.34) 0.2714 
 
CRP day 1     
     < 45 mg/L 
45+ 
58 26 ref (1.0)  
     ≥ 45 mg/L 72 41 1.27 (0.7 - 2.33) 0.4348 
ESR day 1     
     < 31 mm/hr 26 10 ref (1.0)  
     ≥ 31 mm/hr 75 38 1.31 (0.58 - 3.12) 0.513 
Bowel actions day 1     
     < 8 27 12 ref (1.0)  
     ≥ 8 104 57 1.22 (0.58 - 2.7) 0.5849 
Albumin day 1     
      > 30 g/L 88 27 ref (1.0)  
     ≤  30 g/L 
 
 
43 42 3.16 (1.73 - 5.86) 0.0001 
Haemoglobin day 1     
     > 105 g/L 95 51 ref (1.0)  
     ≤ 105 g/L 36 18 0.93 (0.47 -1.80) 0.8328 
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Table 3: Comparison of clinical and laboratory parameters predictive of colectomy at 30 days 
Characteristic Metropolitan (N=131) 
  No 
colectomy 
Colecto
my 
OR (95%CI) p-
value 
N 101 30 
  Bowel actions Day 1 
          6-7 23 4 ref (1.0)
      ≥ 8 78 26 1.86 (0.63 - 
6.98) 
0.261
8 
Bowel actions Day 3 
         <8 74 18 ref (1.0)
      8+ 25 12 1.97 (0.81 - 
4.67) 
0.117
7 
CRP Day 1 
         < 45 mg/L 45 13 ref (1.0)
      ≥ 45 mg/L 55 17 1.07 (0.47 - 
2.48) 
0.872 
CRP Day 3 
         < 45 mg/L 78 19 ref (1.0)
      ≥ 45 mg/L 22 10 1.86 (0.73 - 
4.58) 
0.170
6 
ESR Day 1 
         < 31 mm/hr 23 3 ref (1.0)
      ≥ 31 mm/hr 53 22 3.04 (0.92 - 
14.39) 
0.07 
Albumin Day 1 
          >30 g/L 71 17 ref (1.0)
      ≤ 30 g/L 30 13 1.8 (0.76 - 4.2) 0.162
7 
Haemoglobin Day 1 
         > 105 g/L 76 19 ref (1.0)
      ≤ 105 g/L 25 11 1.76 (0.72 - 
4.19) 
0.193
3 
Characteristic Regional  (N=69 ) 
  No 
colectomy 
Colecto
my 
OR (95%CI) p-
value 
N 37 32 
  Bowel actions Day 1 
          6-7 8 4 ref (1.0)
     ≥ 8 29 28 1.88 (0.52 - 
8.02) 
0.318
8 
Bowel actions Day 3     
     <8 28 13 ref (1.0)  
     8+ 8 18 4.68 (1.65 - 
14.36) 
0.002
7 
CRP Day 1     
     < 45 mg/L 18 8 ref (1.0)  
     ≥ 45 mg/L 18 23 2.81 (1.01 - 
8.36) 
0.042
7 
CRP Day 3     
     < 45 mg/L 31 16 ref (1.0)  
     ≥ 45 mg/L 6 16 4.97 (1.68 - 
16.55) 
0.002
7 
ESR Day 1     
     < 31 mm/hr 7 3 ref (1.0)  
     ≥ 31 mm/hr 20 18 2.02 (0.47 - 
11.16) 
0.324
6 
Albumin Day 1     
      >30 g/L 15 12 ref (1.0)  
     ≤ 30 g/L 22 20 1.13 (0.42 - 
3.06) 
0.796
3 
Haemoglobin Day 1     
     > 105 g/L 25 26 ref (1.0)  
     ≤ 105 g/L 12  6 0.49 (0.15 - 
1.49) 
0.196
8 
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Supplementary Table 1:  Comparison of clinical characteristics of patients who received 
rescue therapy in regional transfer and metropolitan cohorts     
 Characteristic Metro Regional OR (95%CI) p-value 
N 66 45   
Rescue therapy type      
     Ciclosporin 31 15   
     Infliximab 35 30   
Age     
     Mean +/- SD 37.7 (16.3) 35.8 (14.5)  0.54 
Gender     
     Male 32 18   
     Female 34 27 0.71 (0.33 - 1.53) 0.3777 
Smoking status     
    Never 44 23   
    Ex 17 20 0.55 (0.20 - 1.01) 0.051+ 
    Current 5 2  0.134* 
Disease duration (Years)     
     Median (IQR) 2 (9) 1 (3)  0.014 
Disease extent     
     E1/E2 21 7   
     E3 44 38 0.39 (0.14 - 1) 0.0474 
Abdominal radiograph colonic diameter   
     < 5.5cm 56 42   
     ≥ 5.5cm 10 3 2.4 (0.67 - 11.82) 0.1723 
First presentation of UC     
     No 51 31   
     Yes 15 14 0.65 (0.27 - 1.56) 0.3236 
Median duration of IV steroids (days) 8 (5) 9 (5)  0.007 
Median duration of IV steroids (transfer, days)   
     Before transfer  4 (4)   
     After transfer  5 (6)   
CRP day 1     
     < 45 mg/L 29 15   
     ≥ 45 mg/L 37 30 0.64 (0.29 - 1.41) 0.262 
ESR day 1     
     < 31 mm/hr 13 9 (5)   
     ≥ 31 mm/hr 53 36 1.02 (0.38 - 2.65) 0.9686 
Bowel actions day 1     
     < 8 13 8   
     ≥ 8 53 37 0.89 (0.32 - 2.35) 0.7999 
Albumin day 1     
      > 30 g/L 29 12   
     ≤  30 g/L 37 33 0.47 (0.2 - 1.06) 0.0641 
Haemoglobin day 1     
     > 10.5 g/dL 46 32   
     ≤ 10.5 g/dL 20 13 1.07 (0.46 - 2.51) 0.8728 
Truelove and Witts on admission    
     Median number of criteria met (IQR) 2(1) 2(1)   0.271 
     
* p-value from a 2*3 comparison using the Fishers Exact approximation for significance due to expected cell counts less 
than 5. 
 + p-value and odds ratio from a 2 by 2 comparison for never vs ex-smokers. Results from never vs current results not 
shown due to small sample size 
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